Loading...

NovaSeq X And SomaLogic Will Drive Precision Medicine Despite Challenges

Published
13 Apr 25
Updated
07 May 25
n/a
n/a
AnalystHighTarget's Fair Value
n/a
Loading
1Y
-7.7%
7D
-0.9%

Author's Valuation

US$156.5122.9% undervalued intrinsic discount

AnalystHighTarget Fair Value

Shared on 07 May 25

Fair value Decreased 8.78%

Shared on 30 Apr 25

Fair value Decreased 2.24%

AnalystHighTarget made no meaningful changes to valuation assumptions.

Shared on 23 Apr 25

Fair value Increased 16%

AnalystHighTarget has increased future PE multiple from 30.5x to 36.5x.

Shared on 16 Apr 25

Fair value Increased 0.19%

AnalystHighTarget made no meaningful changes to valuation assumptions.